Although trastuzumab is a frontline adjuvant treatment option in combination with chemotherapy in HER2-positive breast cancer patients that achieves better outcomes, it is not an affordable treatment option in sub-Saharan African countries [13]. Here, ERBB2 is linked to breast carcinoma.